ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

NCI advisors approve $144 million program for nanotechnology centers, R01 grants, training. Three to five consortia envisioned.

July 16, 2004

Centers, Groups, Others May Land in DeVita’s Office; Hammer Offers Deal congress Can’t Refuse

February 5, 1988

Final Issue Of ‘77

December 16, 1977

NCI Bioinformatics After Kenneth Buetow: Varmus Launches Fundamental Redesign

January 6, 2012

NCI Critic Epstein Resurfaces TO Blast ‘Cancer Establishment’

February 14, 1992

FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer

December 28, 2012